SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...

Us2.ai receives FDA clearance for Us2.v2,transforming cardiovascular ultrasound analysis
Singapore – April 5, 2024 – Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI, announces FDA clearance for Us2.v2, featuring 45 automated echo parameters, including strain analysis, marking a significant stride in medical innovation.